30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Pharmaceuticals

Hillevax Inc (HLVX)

Track

Stock chart
Ticker: HLVX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
HERSHBERG ROBERT
See Remarks
1 sale — total 21,003 USD
Sale 11 Feb 2025
Value US$817,032.70 | Price 357.53 | Shares 88,994
Sale 11 Feb 2025
Value US$497,234.30 | Price 239.75 | Shares 32,217
Sale 4 Feb 2025
Value US$27,658.26 | Price 1.89 | Shares 14,634
Sale 4 Feb 2025
Value US$7,457.94 | Price 1.89 | Shares 3,946
Planned sale 22 May 2024
Value US$88,372.20 | Price 14.73 | Shares 6,000
Planned sale 21 May 2024
Value US$85,230.00 | Price 14.21 | Shares 6,000
Planned sale 20 May 2024
Value US$92,689.20 | Price 15.45 | Shares 6,000
Planned sale 3 May 2024
Value US$10,233.49 | Price 14.15 | Shares 723
Planned sale 2 May 2024
Value US$84,081.00 | Price 14.01 | Shares 6,000
Planned sale 1 May 2024
Value US$2,456.00 | Price 14.03 | Shares 175
Planned sale 5 Apr 2024
Value US$86,640.00 | Price 14.44 | Shares 6,000
Buy 4 Apr 2024
Value US$128,325.00 | Price 14.50 | Shares 8,850
Planned sale 4 Apr 2024
Value US$88,245.00 | Price 14.71 | Shares 6,000
Planned sale 3 Apr 2024
Value US$89,581.80 | Price 14.93 | Shares 6,000
Buy 28 Mar 2024
Value US$21,225.00 | Price 16.98 | Shares 1,250
Proposed sale 20 Mar 2024
Value US$941,220.00 | Price 17.43 | Shares 54,000
Planned sale 20 Mar 2024
Value US$985,326,000.00 | Price 164,221.00 | Shares 6,000
Planned sale 19 Mar 2024
Value US$104,491.80 | Price 17.42 | Shares 6,000
Planned sale 18 Mar 2024
Value US$105,936.60 | Price 17.66 | Shares 6,000
Planned sale 8 Mar 2024
Value US$111,958.80 | Price 18.66 | Shares 6,000
Planned sale 7 Mar 2024
Value US$110,212.80 | Price 18.37 | Shares 6,000
Planned sale 6 Mar 2024
Value US$113,700.60 | Price 18.95 | Shares 6,000
Planned sale 22 Feb 2024
Value US$90,312.00 | Price 15.05 | Shares 6,000
Planned sale 21 Feb 2024
Value US$89,494.80 | Price 14.92 | Shares 6,000
Planned sale 20 Feb 2024
Value US$89,271.60 | Price 14.88 | Shares 6,000
Planned sale 12 Feb 2024
Value US$91,920.60 | Price 15.32 | Shares 6,000
Proposed sale 12 Feb 2024
Value US$810,000.00 | Price 15.00 | Shares 54,000
Sale 8 Feb 2024
Value US$58,725.59 | Price 14.93 | Shares 3,933
Sale 8 Feb 2024
Value US$173,160.61 | Price 14.93 | Shares 11,597
Sale 8 Feb 2024
Value US$132,382.68 | Price 14.93 | Shares 8,866
Sale 8 Feb 2024
Value US$53,395.04 | Price 14.93 | Shares 3,576
Proposed sale 22 Jan 2024
Value US$1,008,000.00 | Price 14.00 | Shares 72,000
Proposed sale 15 Dec 2023
Value US$155,000.00 | Price 15.50 | Shares 10,000
Sale 15 Dec 2023
Value US$155,000.00 | Price 15.50 | Shares 10,000
Proposed sale 4 Dec 2023
Value US$145,000.00 | Price 14.50 | Shares 10,000
Sale 4 Dec 2023
Value US$145,000.00 | Price 14.50 | Shares 10,000
Proposed sale 1 Dec 2023
Value US$142,000.00 | Price 14.20 | Shares 10,000
Sale 1 Dec 2023
Value US$142,000.00 | Price 14.20 | Shares 10,000
Proposed sale 17 Nov 2023
Value US$140,000.00 | Price 14.00 | Shares 10,000
Sale 17 Nov 2023
Value US$140,000.00 | Price 14.00 | Shares 10,000
Proposed sale 8 Nov 2023
Value US$65,000.00 | Price 13.00 | Shares 5,000
Sale 8 Nov 2023
Value US$65,000.00 | Price 13.00 | Shares 5,000
Proposed sale 21 Jun 2023
Value US$167,400.00 | Price 16.74 | Shares 10,000
Buy 3 May 2022
Value US$30,000,002.00 | Price 17.00 | Shares 1,764,706
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-02-12 2025-02-11 S Sale
2.4
HERSHBERG ROBERT

See Remarks

Executive Director
88,994 -48.5%
357.53
US$817,033 		88,994 -48.5% 357.53 US$817,033
2025-02-12 2025-02-11 S Sale
2.5
Maltbie Shane

Chief Financial Officer

Officer
32,217 +41.2%
239.75
US$497,234 		32,217 +41.2% 239.75 US$497,234
2025-02-12 2025-02-04 S Sale
2.4
HERSHBERG ROBERT

See Remarks

Executive Director
91,618 -44.4%
197.88
US$526,766 		91,618 -44.4% 197.88 US$526,766
2025-02-12 2025-02-04 S Sale
2.5
Maltbie Shane

Chief Financial Officer

Officer
3,946 -4.5%
1.89
US$7,458 		3,946 -4.5% 1.89 US$7,458
2024-05-22 2024-05-22 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.8%
14.73
US$88,372 		6,000 -0.8% 14.73 US$88,372
2024-05-22 2024-05-21 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.8%
14.21
US$85,230 		6,000 -0.8% 14.21 US$85,230
2024-05-22 2024-05-20 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.8%
15.45
US$92,689 		6,000 -0.8% 15.45 US$92,689
2024-05-03 2024-05-03 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
723 -0.1%
14.15
US$10,233 		723 -0.1% 14.15 US$10,233
2024-05-03 2024-05-02 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.8%
14.01
US$84,081 		6,000 -0.8% 14.01 US$84,081
2024-05-03 2024-05-01 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
175 -0.0%
14.03
US$2,456 		175 -0.0% 14.03 US$2,456
2024-04-05 2024-04-05 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.8%
14.44
US$86,640 		6,000 -0.8% 14.44 US$86,640
2024-04-08 2024-04-04 B Purchase
0.8
Frazier Life Sciences X, L.P.
Large shareholder
8,850 +0.1%
14.50
US$128,325 		8,850 +0.1% 14.50 US$128,325
2024-04-05 2024-04-04 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.7%
14.71
US$88,245 		6,000 -0.7% 14.71 US$88,245
2024-04-05 2024-04-03 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.7%
14.93
US$89,582 		6,000 -0.7% 14.93 US$89,582
2024-04-01 2024-03-28 B Purchase
0.5
McLoughlin Sean

Chief Operating Officer

Officer
1,250 +inf%
16.98
US$21,225 		1,250 +inf% 16.98 US$21,225
2024-03-20 2024-03-20 PrS Proposed sale
2.1
ADITYA KOHLI

Director; Officer

Executive Director
54,000
17.43
US$941,220 		54,000 17.43 US$941,220
2024-03-20 2024-03-20 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.7%
164,221.00
US$985,326,000 		6,000 -0.7% 164,221.00 US$985,326,000
2024-03-20 2024-03-19 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.7%
17.42
US$104,492 		6,000 -0.7% 17.42 US$104,492
2024-03-20 2024-03-18 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.7%
17.66
US$105,937 		6,000 -0.7% 17.66 US$105,937
2024-03-08 2024-03-08 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.7%
18.66
US$111,959 		6,000 -0.7% 18.66 US$111,959
2024-03-08 2024-03-07 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.7%
18.37
US$110,213 		6,000 -0.7% 18.37 US$110,213
2024-03-08 2024-03-06 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.7%
18.95
US$113,701 		6,000 -0.7% 18.95 US$113,701
2024-02-22 2024-02-22 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.7%
15.05
US$90,312 		6,000 -0.7% 15.05 US$90,312
2024-02-22 2024-02-21 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.7%
14.92
US$89,495 		6,000 -0.7% 14.92 US$89,495
2024-02-22 2024-02-20 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.7%
14.88
US$89,272 		6,000 -0.7% 14.88 US$89,272
2024-02-14 2024-02-12 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.7%
15.32
US$91,921 		6,000 -0.7% 15.32 US$91,921
2024-02-12 2024-02-12 PrS Proposed sale
2.1
ADITYA KOHLI

Director; Officer

Executive Director
54,000
15.00
US$810,000 		54,000 15.00 US$810,000
2024-02-12 2024-02-08 S Sale
1.9
Borkowski Astrid

Chief Medical Officer

Officer
3,933 -2.4%
14.93
US$58,726 		3,933 -2.4% 14.93 US$58,726
2024-02-12 2024-02-08 S Sale
2.4
HERSHBERG ROBERT

See Remarks

Executive Director
11,597 -1.2%
14.93
US$173,161 		11,597 -1.2% 14.93 US$173,161
2024-02-12 2024-02-08 S Sale
2.1
Kohli Aditya
Non-Executive Director
8,866 -1.1%
14.93
US$132,383 		8,866 -1.1% 14.93 US$132,383
2024-02-12 2024-02-08 S Sale
2.5
Maltbie Shane

Chief Financial Officer

Officer
3,576 -8.1%
14.93
US$53,395 		3,576 -8.1% 14.93 US$53,395
2024-01-22 2024-01-22 PrS Proposed sale
2.4
HERSHBERG ROBERT

Officer; Director

Executive Director
72,000
14.00
US$1,008,000 		72,000 14.00 US$1,008,000
2023-12-18 2023-12-15 PrS Proposed sale
1.9
Astrid Borkowski

Officer

Officer
10,000
15.50
US$155,000 		10,000 15.50 US$155,000
2023-12-18 2023-12-15 S Sale
1.9
Borkowski Astrid

Chief Medical Officer

Officer
10,000 -5.7%
15.50
US$155,000 		10,000 -5.7% 15.50 US$155,000
2023-12-05 2023-12-04 PrS Proposed sale
1.9
Astrid Borkowski

Officer

Officer
10,000
14.50
US$145,000 		10,000 14.50 US$145,000
2023-12-05 2023-12-04 S Sale
1.9
Borkowski Astrid

Chief Medical Officer

Officer
10,000 -5.4%
14.50
US$145,000 		10,000 -5.4% 14.50 US$145,000
2023-12-05 2023-12-01 PrS Proposed sale
1.9
Astrid Borkowski

Officer

Officer
10,000
14.20
US$142,000 		10,000 14.20 US$142,000
2023-12-05 2023-12-01 S Sale
1.9
Borkowski Astrid

Chief Medical Officer

Officer
10,000 -5.1%
14.20
US$142,000 		10,000 -5.1% 14.20 US$142,000
2023-11-27 2023-11-17 PrS Proposed sale
1.9
Borkowski Astrid

Officer

Officer
10,000
14.00
US$140,000 		10,000 14.00 US$140,000
2023-11-20 2023-11-17 S Sale
1.9
Borkowski Astrid

Chief Medical Officer

Officer
10,000 -4.9%
14.00
US$140,000 		10,000 -4.9% 14.00 US$140,000
2023-11-27 2023-11-08 PrS Proposed sale
1.9
Borkowski Astrid

Officer

Officer
5,000
13.00
US$65,000 		5,000 13.00 US$65,000
2023-11-13 2023-11-08 S Sale
1.9
Borkowski Astrid

Chief Medical Officer

Officer
5,000 -2.4%
13.00
US$65,000 		5,000 -2.4% 13.00 US$65,000
2023-06-20 2023-06-21 PrS Proposed sale
1.9
Astrid Borkowski

Officer

Officer
10,000
16.74
US$167,400 		10,000 16.74 US$167,400
2022-05-03 2022-05-03 B Purchase
0.8
Frazier Life Sciences X, L.P.
Large shareholder
1,764,706 +26.1%
17.00
US$30,000,002 		1,764,706 +26.1% 17.00 US$30,000,002
Explore more

More insider trading research around Hillevax Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America